Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mycobacterial 70S ribosome is the essential macromolecular machine responsible for protein synthesis in Mycobacterium species, most notably Mycobacterium tuberculosis (Li et al., 2017, Nature Communications). It consists of two major subunits, the 30S and 50S, which work in tandem to decode mRNA and catalyze the formation of polypeptide chains. This ribosome is a validated therapeutic target because its inhibition leads to bacterial cell death or growth arrest, and it possesses unique structural features—such as specific ribosomal protein extensions and unique rRNA modifications—that distinguish it from other bacterial ribosomes and the eukaryotic 80S ribosome (Wilson, 2014, Nature Reviews Microbiology). Clinically significant antibiotics, including aminoglycosides like streptomycin and oxazolidinones like linezolid, exert their effects by binding to specific sites on the ribosomal subunits to disrupt translation initiation or elongation (WHO, 2023). Resistance to these drugs often arises from mutations in the ribosomal RNA (rRNA) or ribosomal proteins, making the study of this target vital for addressing multi-drug resistant tuberculosis. Recent cryo-electron microscopy studies have highlighted mycobacteria-specific features that are being leveraged to develop more selective and potent anti-tubercular agents.
Drugs targeting the mycobacterial 70S ribosome inhibit protein synthesis by binding to specific sites on either the 30S or 50S subunits. Aminoglycosides bind the 30S subunit to induce mRNA misreading and inhibit translocation (Wilson, 2014, Nature Reviews Microbiology). Oxazolidinones bind the 50S subunit at the peptidyl transferase center (PTC) to prevent the formation of the 70S initiation complex (DrugBank Online, 2024). Macrolides block the nascent peptide exit tunnel on the 50S subunit, leading to premature dissociation of peptidyl-tRNA.
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterial 70S ribosome (70S ribosome).